345 related articles for article (PubMed ID: 23482733)
41. The role of mitochondria in statin-induced myopathy.
Apostolopoulou M; Corsini A; Roden M
Eur J Clin Invest; 2015 Jul; 45(7):745-54. PubMed ID: 25991405
[TBL] [Abstract][Full Text] [Related]
42. Prophylaxis of thromboembolic events in patients with nephrotic syndrome.
Pincus KJ; Hynicka LM
Ann Pharmacother; 2013 May; 47(5):725-34. PubMed ID: 23613095
[TBL] [Abstract][Full Text] [Related]
43. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
44. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
Harper CR; Jacobson TA
Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
[TBL] [Abstract][Full Text] [Related]
45. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
[TBL] [Abstract][Full Text] [Related]
46. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Laaksonen R; Katajamaa M; Päivä H; Sysi-Aho M; Saarinen L; Junni P; Lütjohann D; Smet J; Van Coster R; Seppänen-Laakso T; Lehtimäki T; Soini J; Oresic M
PLoS One; 2006 Dec; 1(1):e97. PubMed ID: 17183729
[TBL] [Abstract][Full Text] [Related]
47. Managing the underestimated risk of statin-associated myopathy.
Rallidis LS; Fountoulaki K; Anastasiou-Nana M
Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
49. Approximate equivalent rosuvastatin doses for temporary statin interchange programs.
Kendrach MG; Kelly-Freeman M
Ann Pharmacother; 2004; 38(7-8):1286-92. PubMed ID: 15187217
[TBL] [Abstract][Full Text] [Related]
50. Interaction potential between clarithromycin and individual statins-A systematic review.
Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
[TBL] [Abstract][Full Text] [Related]
51. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
52. The high-dose rosuvastatin once weekly study (the HD-ROWS).
Backes JM; Gibson CA; Ruisinger JF; Moriarty PM
J Clin Lipidol; 2012; 6(4):362-7. PubMed ID: 22836073
[TBL] [Abstract][Full Text] [Related]
53. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
54. Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.
Boonmuang P; Nathisuwan S; Chaiyakunapruk N; Suwankesawong W; Pokhagul P; Teerawattanapong N; Supsongserm P
Drug Saf; 2013 Sep; 36(9):779-87. PubMed ID: 23615756
[TBL] [Abstract][Full Text] [Related]
55. Statin-induced myopathy: the two faces of Janus.
Arora R; Liebo M; Maldonado F
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):105-12. PubMed ID: 16891287
[TBL] [Abstract][Full Text] [Related]
56. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
[TBL] [Abstract][Full Text] [Related]
58. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
59. Approach to the patient who is intolerant of statin therapy.
Eckel RH
J Clin Endocrinol Metab; 2010 May; 95(5):2015-22. PubMed ID: 20444930
[TBL] [Abstract][Full Text] [Related]
60. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.
Kobayashi M; Chisaki I; Narumi K; Hidaka K; Kagawa T; Itagaki S; Hirano T; Iseki K
Life Sci; 2008 Apr; 82(17-18):969-75. PubMed ID: 18402982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
